Overview

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

Status:
Completed
Trial end date:
2017-02-23
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Galderma R&D
Treatments:
Trifarotene